-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, U3Y29146y2ytjTce2tRthUpeUUA/2ER6MnkM1Gd8P8eltcNTrf/NUL8LWrerKRVz F8GNQjTZmUQSHjcjBC9S9A== 0000950135-08-001308.txt : 20080228 0000950135-08-001308.hdr.sgml : 20080228 20080228170346 ACCESSION NUMBER: 0000950135-08-001308 CONFORMED SUBMISSION TYPE: FWP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20080228 DATE AS OF CHANGE: 20080228 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN IDEC INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: FWP SEC ACT: 1934 Act SEC FILE NUMBER: 333-149379 FILM NUMBER: 08651511 BUSINESS ADDRESS: STREET 1: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6176792000 MAIL ADDRESS: STREET 1: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN IDEC INC. CENTRAL INDEX KEY: 0000875045 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330112644 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: FWP BUSINESS ADDRESS: STREET 1: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6176792000 MAIL ADDRESS: STREET 1: 14 CAMBRIDGE CENTER CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN IDEC INC DATE OF NAME CHANGE: 20031112 FORMER COMPANY: FORMER CONFORMED NAME: IDEC PHARMACEUTICALS CORP / DE DATE OF NAME CHANGE: 19970530 FWP 1 b66289fwfwp.htm BIOGEN IDEC INC. fwp
 

Filed pursuant to Rule 433
Registration No.: 333-149379
February 28, 2008
Biogen Idec Inc.
$6.000% Senior Notes Due 2013
$6.875% Senior Notes Due 2018
PRICING TERM SHEET
6.000% Senior Notes Due 2013
     
Issuer:
  Biogen Idec Inc.
 
    
Ratings:
  Baa3 / BBB (Moody’s/S&P)
 
    
Principal Amount:
  $450,000,000
 
    
Maturity Date:
  March 1, 2013
 
    
Trade Date:
  February 28, 2008
 
    
Original Issue Date (Settlement):
  March 4, 2008
 
    
Interest Accrual Commencement Date:
  March 4, 2008
 
    
Issue Price (Price to Public):
  99.886%
 
    
Interest Rate:
  6.000% per annum
 
    
Interest Payment Dates:
  Semi-annually, each March 1 and September 1, commencing September 1, 2008
 
    
Interest Rate Adjustment:
  The interest rate payable on the 2013 notes will be subject to adjustments from time to time if either Moody’s or S&P downgrades (or subsequently upgrades) the debt rating assigned to that series of notes below Baa3 or BBB-, subject to the limitation described under “Description of Notes—Interest Rate Adjustment” in the preliminary prospectus supplement.
 
    
Treasury Benchmark:
  T 2.875% 01/31/2013
 
    
Spread to Benchmark:
  325 bps
 
    
Benchmark Yield:
  2.777%
 
    
Optional Redemption:
  Make Whole call as set forth in the preliminary prospectus supplement (treasury rate plus 50 basis points)
 
    
Change of Control:
  Upon the occurrence of a Change of Control Triggering Event (as defined in the preliminary prospectus supplement to which this pricing term sheet relates), Biogen Idec Inc. will be required to make an offer to purchase the 2013 notes at a price equal to 101% of their principal amount plus accrued and unpaid interest to the date of repurchase
 
    
Minimum Denomination:
  $2,000 and integral multiples of $1,000 in excess thereof

 

 

     
Business Day:
  New York
 
    
CUSIP:
  09062XAA1
 
    
ISIN:
  US09062XAA19
 
    
Joint Book-Running Managers:
  Goldman, Sachs & Co.
Merrill Lynch, Pierce, Fenner & Smith Incorporated
 
    
Senior Co-Managers:
  Banc of America Securities LLC
Morgan Stanley & Co. Incorporated
 
    
Co-Managers:
  Citigroup Global Markets Inc.
J.P. Morgan Securities Inc.
Lehman Brothers Inc.
UBS Securities LLC
 
    
Global Settlement:
  Through The Depository Trust Company, including Euroclear or Clearstream, Luxembourg, as participants
6.875% Senior Notes Due 2018
     
Issuer:
  Biogen Idec Inc.
 
    
Ratings:
  Baa3 / BBB (Moody’s/S&P)
 
    
Principal Amount:
  $550,000,000
 
    
Maturity Date:
  March 1, 2018
 
    
Trade Date:
  February 28, 2008
 
    
Original Issue Date (Settlement):
  March 4, 2008
 
    
Interest Accrual Commencement Date:
  March 4, 2008
 
    
Issue Price (Price to Public):
  99.184%
 
    
Interest Rate:
  6.875% per annum
 
    
Interest Payment Dates:
  Semi-annually, each March 1 and September 1, commencing September 1, 2008
 
    
Interest Rate Adjustment:
  The interest rate payable on the 2018 notes will be subject to adjustments from time to time if either Moody’s or S&P downgrades (or subsequently upgrades) the debt rating assigned to that series of notes below Baa3 or BBB-, subject to the limitation described under “Description of Notes—Interest Rate Adjustment” in the preliminary prospectus supplement.
 
    
Treasury Benchmark:
  T 3.500% 02/15/2018
 
    
Spread to Benchmark:
  325 bps
 
    
Benchmark Yield:
  3.740%

2

 

     
Optional Redemption:
  Make Whole call as set forth in the preliminary prospectus supplement (treasury rate plus 50 basis points)
 
    
Change of Control:
  Upon the occurrence of a Change of Control Triggering Event (as defined in the preliminary prospectus supplement to which this pricing term sheet relates), Biogen Idec Inc. will be required to make an offer to purchase the 2018 notes at a price equal to 101% of their principal amount plus accrued and unpaid interest to the date of repurchase
 
    
Minimum Denomination:
  $2,000 and integral multiples of $1,000 in excess thereof
 
    
Business Day:
  New York
 
    
CUSIP:
  09062XAB9
 
    
ISIN:
  US09062XAB91
 
    
Joint Book-Running Managers:
  Goldman, Sachs & Co.
Merrill Lynch, Pierce, Fenner & Smith Incorporated
 
    
Senior Co-Managers:
  Banc of America Securities LLC
 
    
Co-Managers:
  Citigroup Global Markets Inc.
J.P. Morgan Securities Inc.
Lehman Brothers Inc.
UBS Securities LLC
 
    
Global Settlement:
  Through The Depository Trust Company, including Euroclear or Clearstream, Luxembourg, as participants
None of the securities ratings is a recommendation to buy, sell or hold the notes. Each rating may be subject to revision or withdrawal at any time, and should be evaluated independently of any other rating.
The issuer has filed a registration statement (including a prospectus) with the SEC for the offerings to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and these offerings. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offerings will arrange to send you the prospectus if you request it by calling Goldman, Sachs & Co. toll free at 1-866-471-2526 or Merrill Lynch, Pierce, Fenner & Smith Incorporated toll free at 1-866-500-5408.

3

-----END PRIVACY-ENHANCED MESSAGE-----